Amphastar Pharmaceuticals (AMPH) Current Assets (2013 - 2026)

Amphastar Pharmaceuticals has reported Current Assets for 14 years, with the latest figure at $631.0 million in Q2 2026.

• On a quarterly basis, Current Assets rose 8.63% year-over-year to $631.0 million in Q2 2026; TTM through Jun 2026 was $631.0 million, a 8.63% increase from a year earlier, with the FY2025 full-year figure at $636.0 million, up 19.09% from the prior year.
• Current Assets was $631.0 million for Q2 2026 at Amphastar Pharmaceuticals, roughly flat from $633.7 million in the prior quarter.
• The five-year high for Current Assets was $639.5 million in Q3 2025, with the low at $364.4 million in Q1 2022.
• Average Current Assets over 5 years is $508.6 million, with a median of $538.5 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Current Assets surged 41.33% in 2023, then climbed 0.54% in 2024.
• Over 5 years, Current Assets stood at $378.3 million in 2022, then gained by 29.41% to $489.6 million in 2023, then advanced by 9.08% to $534.1 million in 2024, then grew by 19.09% to $636.0 million in 2025, then retreated by 0.8% to $631.0 million in 2026.
• The last three Current Assets figures came in at $631.0 million (Q2 2026), $633.7 million (Q1 2026), and $636.0 million (Q4 2025), per Business Quant data.